Advertisement
Research Article| Volume 68, ISSUE 1, P140-146, January 2018

Download started.

Ok

Association between non-alcoholic fatty liver disease and cancer incidence rate

  • Gi-Ae Kim
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Han Chu Lee
    Correspondence
    Corresponding authors. Addresses: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Tel.: +82 2 3010 3915; fax: +82 2 485 5782 (H.C. Lee) or Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Tel.: +82 2 3010 4918; fax: +82 2 3010 4917 (J. Choe).
    Affiliations
    Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Jaewon Choe
    Correspondence
    Corresponding authors. Addresses: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Tel.: +82 2 3010 3915; fax: +82 2 485 5782 (H.C. Lee) or Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Tel.: +82 2 3010 4918; fax: +82 2 3010 4917 (J. Choe).
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Min-Ju Kim
    Affiliations
    Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Min Jung Lee
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Hye-Sook Chang
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • In Young Bae
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Hong-Kyu Kim
    Affiliations
    Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Jihyun An
    Affiliations
    Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Ju Hyun Shim
    Affiliations
    Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Kang Mo Kim
    Affiliations
    Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Young-Suk Lim
    Affiliations
    Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
Published:November 14, 2017DOI:https://doi.org/10.1016/j.jhep.2017.09.012

      Highlights

      • NAFLD was associated with HCC development.
      • NAFLD was associated with colorectal cancer development in males.
      • NAFLD was associated with breast cancer development in females.
      • High NFS and high FIB-4 score were associated with developing all cancers and HCC.

      Background & Aims

      Little is known about the association between non-alcoholic fatty liver disease (NAFLD) and cancer development. This study investigated the cancer incidence rates in NAFLD and analysed the association between NAFLD and cancer development.

      Methods

      This historical cohort study included subjects who were followed up for >1 year after having a heath checkup at a tertiary hospital in Korea from September 1, 2004 to December 31, 2005. NAFLD was diagnosed by ultrasonographic detection of hepatic steatosis in the absence of other known liver disease, including alcoholic or viral hepatitis. Cox proportional hazards regression model was conducted to assess the association between NAFLD and cancer development.

      Results

      Of 25,947 subjects, 8,721 (33.6%) had NAFLD. During the total follow-up of 164,671 person-years (median 7.5 years), the cancer incidence rate of the NAFLD group was higher than that of the non-NAFLD group (782.9 vs. 592.8 per 100,000 person-years; hazard ratio [HR] 1.32; 95% confidence interval [CI] 1.17–1.49; p <0.001). When demographic and metabolic factors were adjusted for, NAFLD showed a strong association with three cancers: hepatocellular carcinoma ([HCC]; HR 16.73; 95% CI 2.09–133.85; p = 0.008), colorectal cancer in males (HR 2.01; 95% CI 1.10–3.68; p = 0.02), and breast cancer in females (HR 1.92; 95% CI 1.15–3.20; p = 0.01). A high NAFLD fibrosis score (NFS) and a high fibrosis-4 (FIB-4) score were associated with the development of all cancers and HCC.

      Conclusion

      NAFLD was associated with the development of HCC, colorectal cancer in males, and breast cancer in females. A high NFS and a high FIB-4 score showed a strong association with the development of all cancers and HCC.

      Lay summary

      Non-alcoholic fatty liver disease (NAFLD) is associated with developing hepatocellular carcinoma (HCC). There have been limited data on the association between NAFLD and extrahepatic cancers. This study demonstrated that patients with NAFLD showed a higher association with the development of HCC, colorectal cancer in males, and breast cancer in females. A high NAFLD fibrosis score and a high fibrosis-4 score showed a strong association with the development of all cancers and HCC.

      Graphical abstract

      Keywords

      Linked Article

      • The role of NAFLD in extrahepatic malignancies: The importance of ruling out the effect of obesity
        Journal of HepatologyVol. 68Issue 5
        • Preview
          We read with great interest the article by Kim et al.1 Non-alcoholic fatty liver disease (NAFLD) is strongly associated with metabolic disorders such as insulin resistance, diabetes and cardiovascular disease, suggesting that NAFLD is an important factor in extrahepatic complications. Kim et al. not only confirmed that NAFLD is closely related to the development of hepatocellular carcinoma, but also demonstrated that NAFLD is a risk factor for extrahepatic malignancies such as male colorectal carcinoma and female breast cancer.
        • Full-Text
        • PDF
      • Reply to: “The role of NAFLD in extrahepatic malignancies: The importance of ruling out the effect of obesity”
        Journal of HepatologyVol. 68Issue 5
        • Preview
          We thank Bo Zheng et al. for their interest in our study and for providing a valuable comment.1 Our study investigated the little understood relationship between non-alcoholic fatty liver disease (NAFLD) and extrahepatic cancers,2 and found that NAFLD was highly associated with the development of hepatocellular carcinoma (HCC), colorectal cancer in males, and breast cancer in females. This association suggests that NAFLD can serve as a risk factor of extrahepatic malignancies.
        • Full-Text
        • PDF
      • NAFLD and cancer: More cause for concern?
        Journal of HepatologyVol. 68Issue 1
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) is likely to become the most prevalent liver disease in many countries,1,2 yet clinicians are struggling to determine exactly why they should care about NAFLD. Is it merely a bystander – a manifestation of the metabolic syndrome resulting in cardiovascular disease – or is it a liver disease in its own right?3
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Younossi Z.M.
        • Koenig A.B.
        • Abdelatif D.
        • Fazel Y.
        • Henry L.
        • Wymer M.
        Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
        Hepatology. 2016; 64: 73-84
        • European Association for the Study of the Liver
        • European Association for the Study of D
        • European Association for the Study of O
        EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
        J Hepatol. 2016; 64: 1388-1402
        • Korean Association for the Study of the Liver
        KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.
        Clin Mol Hepatol. 2013; 19: 325-348
        • Armstrong M.J.
        • Adams L.A.
        • Canbay A.
        • Syn W.K.
        Extrahepatic complications of nonalcoholic fatty liver disease.
        Hepatology. 2014; 59: 1174-1197
        • Byrne C.D.
        • Targher G.
        NAFLD: a multisystem disease.
        J Hepatol. 2015; 62: S47-S64
        • Chacko K.R.
        • Reinus J.
        Extrahepatic complications of nonalcoholic fatty liver disease.
        Clin Liver Dis. 2016; 20: 387-401
        • Kim D.
        • Kim W.R.
        • Kim H.J.
        • Therneau T.M.
        Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
        Hepatology. 2013; 57: 1357-1365
        • Younossi Z.M.
        • Otgonsuren M.
        • Henry L.
        • Venkatesan C.
        • Mishra A.
        • Erario M.
        • et al.
        Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
        Hepatology. 2015; 62: 1723-1730
        • Wong V.W.
        • Wong G.L.
        • Tsang S.W.
        • Fan T.
        • Chu W.C.
        • Woo J.
        • et al.
        High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis.
        Gut. 2011; 60: 829-836
        • Ahn J.S.
        • Sinn D.H.
        • Min Y.W.
        • Hong S.N.
        • Kim H.S.
        • Jung S.H.
        • et al.
        Non-alcoholic fatty liver diseases and risk of colorectal neoplasia.
        Aliment Pharmacol Ther. 2017; 45: 345-353
        • Saverymuttu S.H.
        • Joseph A.E.
        • Maxwell J.D.
        Ultrasound scanning in the detection of hepatic fibrosis and steatosis.
        Br Med J. 1986; 292: 13-15
        • Angulo P.
        • Hui J.M.
        • Marchesini G.
        • Bugianesi E.
        • George J.
        • Farrell G.C.
        • et al.
        The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
        Hepatology. 2007; 45: 846-854
        • Sterling R.K.
        • Lissen E.
        • Clumeck N.
        • Sola R.
        • Correa M.C.
        • Montaner J.
        • et al.
        Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
        Hepatology. 2006; 43: 1317-1325
        • Seo H.J.
        • Oh I.H.
        • Yoon S.J.
        A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea.
        Asian Pac J Cancer Prev. 2012; 13: 6163-6168
        • Sorensen H.T.
        • Mellemkjaer L.
        • Jepsen P.
        • Thulstrup A.M.
        • Baron J.
        • Olsen J.H.
        • et al.
        Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study.
        J Clin Gastroenterol. 2003; 36: 356-359
        • Kawamura Y.
        • Arase Y.
        • Ikeda K.
        • Seko Y.
        • Imai N.
        • Hosaka T.
        • et al.
        Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
        Am J Gastroenterol. 2012; 107: 253-261
        • Mittal S.
        • El-Serag H.B.
        • Sada Y.H.
        • Kanwal F.
        • Duan Z.
        • Temple S.
        • et al.
        Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease.
        Clin Gastroenterol Hepatol. 2016; 14 (e121): 124-131
        • Noureddin M.
        • Rinella M.E.
        Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
        Clin Liver Dis. 2015; 19: 361-379
        • Piscaglia F.
        • Svegliati-Baroni G.
        • Barchetti A.
        • Pecorelli A.
        • Marinelli S.
        • Tiribelli C.
        • et al.
        Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.
        Hepatology. 2016; 63: 827-838
        • Sanna C.
        • Rosso C.
        • Marietti M.
        • Bugianesi E.
        Non-alcoholic fatty liver disease and extra-hepatic cancers.
        Int J Mol Sci. 2016; 17
        • Hui J.M.
        • Hodge A.
        • Farrell G.C.
        • Kench J.G.
        • Kriketos A.
        • George J.
        Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.
        Hepatology. 2004; 40: 46-54
        • Gilbert C.A.
        • Slingerland J.M.
        Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression.
        Annu Rev Med. 2013; 64: 45-57
        • Campbell P.T.
        • Deka A.
        • Jacobs E.J.
        • Newton C.C.
        • Hildebrand J.S.
        • McCullough M.L.
        • et al.
        Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men.
        Gastroenterology. 2010; 139: 1138-1146
        • Yamamoto S.
        • Nakagawa T.
        • Matsushita Y.
        • Kusano S.
        • Hayashi T.
        • Irokawa M.
        • et al.
        Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia.
        Diabetes Care. 2010; 33: 184-189
        • Chiu H.M.
        • Lin J.T.
        • Shun C.T.
        • Liang J.T.
        • Lee Y.C.
        • Huang S.P.
        • et al.
        Association of metabolic syndrome with proximal and synchronous colorectal neoplasm.
        Clin Gastroenterol Hepatol. 2007; 5 (Quiz 141): 221-229
        • Renehan A.G.
        • Tyson M.
        • Egger M.
        • Heller R.F.
        • Zwahlen M.
        Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.
        Lancet. 2008; 371: 569-578
        • Arnold M.
        • Pandeya N.
        • Byrnes G.
        • Renehan A.G.
        • Stevens G.A.
        • Ezzati M.
        • et al.
        Global burden of cancer attributable to high body-mass index in 2012: a population-based study.
        Lancet Oncol. 2015; 16: 36-46
        • Lohmann A.E.
        • Goodwin P.J.
        • Chlebowski R.T.
        • Pan K.
        • Stambolic V.
        • Dowling R.J.
        Association of obesity-related metabolic disruptions with cancer risk and outcome.
        J Clin Oncol. 2016; 34: 4249-4255
        • Rosato V.
        • Bosetti C.
        • Talamini R.
        • Levi F.
        • Montella M.
        • Giacosa A.
        • et al.
        Metabolic syndrome and the risk of breast cancer in postmenopausal women.
        Ann Oncol. 2011; 22: 2687-2692
        • Agnoli C.
        • Berrino F.
        • Abagnato C.A.
        • Muti P.
        • Panico S.
        • Crosignani P.
        • et al.
        Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study.
        Nutr Metab Cardiovasc Dis. 2010; 20: 41-48
        • Lawlor D.A.
        • Smith G.D.
        • Ebrahim S.
        Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study.
        Cancer Causes Control. 2004; 15: 267-275
        • Starley B.Q.
        • Calcagno C.J.
        • Harrison S.A.
        Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
        Hepatology. 2010; 51: 1820-1832
        • Park S.
        • Oh C.M.
        • Cho H.
        • Lee J.Y.
        • Jung K.W.
        • Jun J.K.
        • et al.
        Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study.
        BMJ. 2016; 355: i5745
        • Dasarathy S.
        • Dasarathy J.
        • Khiyami A.
        • Joseph R.
        • Lopez R.
        • McCullough A.J.
        Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study.
        J Hepatol. 2009; 51: 1061-1067
        • Choi S.Y.
        • Kim D.
        • Kim H.J.
        • Kang J.H.
        • Chung S.J.
        • Park M.J.
        • et al.
        The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans.
        Am J Gastroenterol. 2009; 104: 1953-1960